(24/7 MARKET NEWS) – ThermoGenesis Holdings, Inc. (NASDAQ: THMO) stated, this morning, that it’s rolling out a new facility in the Sacramento metro area, containing 12 class-7 ReadyStart cGMP Suites, available for lease by early-stage life science and cell gene therapy (“CGT”) companies, part of ThermoGenesis’ previously announced plan to transform from a medical device company to a contract development and manufacturing organization (“CDMO”) in the cell gene therapy field. The facility is expected to be available for customers in the second or third quarter of this year. If fully occupied, the facility is anticipated to generate an estimated $10-16 million in annual revenue.
ThermoGenesis is trading at $3.58, up $1.47 (+69.67%), on 1 million premarket shares.
Its 52-week trading range is $2.11 to $40.491. It’s blown through many of its recent resistance points and, although this may be a bit of a stretch, if it can break into the $6 trading range, it could begin to fill in the gap to the $10 range.
24/7 MARKET NEWS, INC Disclaimer
24/7 MARKET NEWS (“24/7 MN”) is dedicated to covering various underreported segments of the stock markets. Our goal is to help you to better understand these markets, but 24/7 MN is neither an investment advisor nor a financial advisor, and no information provided here is to be interpreted as a suggestion to buy or sell stocks or other investment products. All opinions, news, research, analysis, prices or other information contained on 247marketnews.com, its press releases, or other services are provided for educational purposes only and do not constitute investment advice. You are solely responsible for the investment decisions you make.
Please go to www.247marketnews.com or https://www.247marketnews.com/terms-disclaimer/ for further information.
